The long acting monoclonal antibody nirsevimab (marketed as Beyfortus) reduced respiratory syncytial virus associated hospital admissions in infants by 83%, a study has found.1
More than 8000 infants aged 12 months or under in France, Germany, and the UK took part in the study and were randomly assigned to either receive nirsevimab (4037 infants) or standard care (no intervention, 4021 infants) before or during their first RSV season (September and October 2022).
The study, funded by the drug companies Sanofi and AstraZeneca, reported that 11 infants (0.3%) in the nirsevimab group and 60 (1.5%) in the standard group were …
President Ferdinand Marcos Jr.’s appointment of Senator Sonny Angara as the new Secretary of the…
Taiwan has detected at least 127 Chinese military aircraft operating near the islandTaipei: Taiwan on…
New evidence from the US has backed up previous findings that as of early 2023,…
1) Move More Sedentary people burn about one-third less calories per day. By simply taking…
Mason Amos is leaving Ateneo Blue Eagles after just one UAAP season with the team…
Photo credit: Universal Pictures International Whether it’s a catchy upbeat tune like “Happy” or a…
This website uses cookies.